The US Health Resources and Services Administration unlawfully denied the drugmaker’s request to audit certain health systems when it sought to examine which patients were receiving their discounted medicines under the 340B Drug Pricing Program, AbbVie said in a complaint filed Wednesday in the US District Court for the District of Columbia.
“At its core, this suit seeks to restore integrity to the federal 340B ...